News

AUPN Leading Edge Episode 2 features Clifton Gooch, MD, and Charles Lockwood, MD, who explore making the leap from chair to dean. [LISTEN TIME: 25 minutes]

Already FDA approved for the treatment of insomnia in adults, lemborexant’s ability to improve sleep outcomes in the elderly was highlighted in a study presented at SLEEP 2020.

The chief medical officer at Cure SMA offers insight on the current SMA therapeutic landscape and what the organization is focused on going forward.

In part 2 of this interview, Marwan Sabbagh, MD, provides insight on what he feels is the most promising field of research in Alzheimer disease right now.

After wearing the noninvasive device, 62% of TETRAS-rated patients and 68% of BF-ADL-rated patients whose tremors were rated as "severe" or "moderate" improved to "mild" or "slight" scores.

Managing narcolepsy via behavioral strategies to improve excessive daytime sleepiness may be challenging but has shown some added efficacy when combined with pharmacological treatment for EDS.

The chief research officer and epilepsy specialist at Cleveland Clinic detailed how recent study findings might impact the patient perspective on epilepsy surgery.

New biomarkers of disease activity may help better vet investigational therapies aimed at slowing the insidious neurodegeneration seen in primary progressive multiple sclerosis.

Neurology News Network for the week ending August 29, 2020.

With a positive track record in ALS, the investigational agent now sets its sights on the Alzheimer disease pipeline.

Healthy lifestyle choices are an integral part of disease management for patients with narcolepsy who face an increased prevalence of comorbid cardiovascular and metabolic conditions.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Rajesh Pahwa, MD.

Benefit from lemborexant was evident after 1 month of switching from placebo to the active treatment and was sustained through the entirety of the 12-month trial.

Multiple abstracts at SLEEP 2020 show CBT-I’s success in aiding women with insomnia, including those going through pregnancy, and those who are veterans both with and without PTSD.

The director of the Sagol Center for Hyperbaric Medicine and Research at Yitzhak Shamir Medical Center discussed how hyperbaric oxygen therapy is being used to attempt to improve the damage from neurodegeneration.

Could expanding insights into the pathophysiology of autoimmune epilepsy offer seizure-free hope for patients?

Howard Fillit, MD, founding executive director and chief science officer of the Alzheimer's Drug Discovery Foundation and clinical professor of geriatric medicine and palliative care, medicine, and neuroscience at Mount Sinai School of Medicine, detailed the role telemedicine plays in treating Alzheimer disease.

The first-in-class CH24H inhibitor was associated with a reduction in seizures and seizure frequency in an early analysis of the phase 2 ELEKTRA study, with plans to initiate the move to phase 3 in Dravet syndrome.

A group of international experts in the treatment of multiple sclerosis offer their varying viewpoints on the history, identification, and management of the disease.

Increased consumption of vegetables, nuts, and moderate alcohol intake are each inversely associated with the odds of 3 or more prodromal features that precede Parkinson disease.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed how Alzheimer disease research may change if aducanumab becomes approved.

In part 2 of this interview, Hubert Fernandez, MD, director of the Center for Neurological Restoration at Cleveland Clinic, detailed the greatest unmet needs as well as the utility of deep brain stimulation in patients with Parkinson disease.

The vice president of science and medical at Dreem offered his opinion on how the company’s headband device can improve how sleep studies are conducted.

The authors noted that taken together, the findings suggest that either hearing impairment may affect brain atrophy and neuropathologic burden or that underlying pathologies may impair functional hearing abilities, even prior to dementia onset.

Efforts to cut through regulatory red tape will help ensure earlier access to potentially lifesaving treatments.

The investgators noted that the absences before the tonic-clonic convulsions can be as short as 5 seconds, suggesting they may be more frequently occurring than those being observed or reported.

Recognition of the distinct neuroanatomical patterns, symptoms, and rates of progression within different biotypes can play a pivotal role in the implementation of precision medicine for Parkinson disease.

The director emeritus of the Lou Ruvo Center for Brain Health at Cleveland Clinic and vice chair of the Department of Brain Health at the University of Nevada-Las Vegas discussed the role repurposed agents play in Alzheimer disease development.